AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescent angiography
Description: Ophthalmic examination
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Visometry
Description: Ophthalmic examination
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Refractometry
Description: Ophthalmic examination
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Slit lamp examination
Description: Ophthalmic examination
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Ophthalmoscopy
Description: Ophthalmic examination
Study NCT04245072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OKT
Description: Ophthalmic examination
Study NCT02127710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6094
Description: AZD6094 is a potent and selective small molecule mesenchymal epithelial transition (c-MET) kinase inhibitor.
Study NCT02063711 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Study NCT02228434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Monitoring and Tailored prescription
Study NCT02228434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Happy 10 program
Study NCT02228434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Specified nutrition education
Study NCT02228434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: General Health Education
Study NCT01321060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Aspiration
Study NCT01321060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Catheter drainage
Study NCT01321060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative treatment
Description: Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OE 10 mg amlodipine besylate tablet
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OE 10 mg amlodipine besylate tablet
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OE 200 mg celecoxib capsule
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo for OE amlodipine besylate tablet
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matched placebo for OE celecoxib capsule
Study NCT02979197 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Matched placebo for OE celecoxib capsule
Study NCT02744703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total-etch adhesive
Description: comparator use of total-etch adhesive
Study NCT02744703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPE-T
Description: experimental group
Study NCT02744703 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: self-etch adhesive
Description: comparator use of total-etch adhesive
Study NCT02744703 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAPE-S
Description: experimental group
Study NCT01254071 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)
Description: In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
Study NCT03049618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03049618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03049618 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant EphB4-HSA Fusion Protein
Description: Given IV
Study NCT03643159 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Abilify MyCite - Digital Medicine System
Description: The Abilify MyCite system is a drug-device combination product comprised of aripiprazole (an atypical antipsychotic) tablets embedded with a sensor that communicates with a patch (wearable sensor) and a medical software application with collected information (ingestion, mood, activity, rest) tracked and summarized for participants, healthcare providers, and potential caregivers. Abilify MyCite is intended to track drug ingestion and is indicated for the treatment of adults with schizophrenia (SCH), bipolar 1 disorder (BP1) (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with major depressive disorder (MDD).
Study NCT03643159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole or other oral antipsychotics
Description: For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
Study NCT03643159 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aripiprazole or other oral antipsychotics
Description: For the treatment of adults with SCH, BP1 (acute treatment of adults with manic and mixed episodes or maintenance treatment of adults), and adjunctive treatment of adults with MDD.
Study NCT02605304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir/sofosbuvir
Description: Participants were prescribed one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
Study NCT02605304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Based on weight at entry:~For weight \<75 kg, participants were prescribed 1000 mg of RBV per day, divided into two doses to be taken orally.~For weight ≥75 kg: participants were prescribed 1200 mg of RBV per day, divided into two doses to be taken orally.
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF)
Description: 1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
Study NCT03356158 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Injection, q.w., 20 mg: 100 ml
Study NCT00601523 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
Study NCT00601523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole
Description: ER 0.375-4,5 mg
Study NCT02702193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SET-R/Healthy Home
Description: SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
Study NCT02558738 — intervention group
Intervention type: DEVICE
Intervention: ear spray
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Maintenance Phase
Description: 0.5-1 g/m\^2 IV pulse once every 3 months
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Induction Phase
Description: 0.5 - 1 g/m\^2 IV pulse once per month
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Induction Phase
Description: 0.5 - 1 g/m\^2 IV pulse once per month
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
Study NCT02081183 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
Study NCT04339075 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires to access the quality of life (EQ5D, VCSS, CVVQ, CIVIQ, Patient satisfaction survey)
Study NCT00041717 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fampridine-SR
Description: 25mg bid (twice daily)
Study NCT00041717 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02329873 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory rehabilitation exercise training
Description: The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
Study NCT00629694 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: adenoidectomy, myringotomy, tubes insertion
Description: adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
Study NCT00629694 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: A-M
Description: adenoidectomy and myringotomy alone
Study NCT04210336 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PAPILOCARE
Description: Papilocare®: Vaginal Gel based on Coriolus versicolor, medical device class IIa.~Route of administration: topical (vaginal). Papilocare® consists of the following ingredients: hyaluronic acid niosomes, β-glucans (magnolol, honokiol and carboxymethyl betaglucan) niosomes, BioEcolia® (Alpha-oligoglycan), Coriolus versicolor, Azadirachta indica (Neem) extract, Centella asiatica and Aloe vera.
Study NCT04210336 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: The placebo consists of a carrier gel with the absence of the active ingredients of Papilocare®.
Study NCT02415296 — intervention group
Intervention type: OTHER
Intervention: stage 1
Description: The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
Study NCT02415296 — intervention group
Intervention type: OTHER
Intervention: stage 2
Description: The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
Study NCT02415296 — intervention group
Intervention type: OTHER
Intervention: stage 3
Description: The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
Study NCT03363828 — intervention group
Intervention type: DRUG
Intervention: Estrofem
Description: Patients will be asked to obtain self-collected vaginal swabs from the mid-vagina from the beginning of their Estrofem® treatment
Study NCT02995681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
Study NCT02995681 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary rehab
Description: Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
Study NCT02995681 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulmonary rehab
Description: Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
Study NCT02851680 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Study NCT02851680 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: blood samples
Study NCT00676273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-Obturator (TVT-O)
Description: sub urethral sling
Study NCT00676273 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-Secur (TVT-S) (Hammock method)
Description: suburethral sling
Study NCT01124058 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose).
Study NCT01124058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR.
Study NCT03992313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facility-based HCV rapid test
Description: HCV rapid tests will be done in the health center
Study NCT03992313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plasmatic HCV viral load
Description: HCV viral load will be done in provincial hospital on plasma using GenXpert
Study NCT03992313 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DBS HCV viral load
Description: HCV viral load will be done in Phnom Penh by DBS using Omunis kit
Study NCT01811368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV
Study NCT01811368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ibritumomab tiuxetan
Description: Given IV
Study NCT01811368 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-thymocyte globulin
Description: Given IV
Study NCT01811368 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total nodal irradiation
Description: Undergo TLI
Study NCT01811368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT01811368 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: Undergo allogeneic peripheral blood stem cell transplant
Study NCT01811368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Description: Given PO or IV
Study NCT01811368 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: Given PO or IV
Study NCT00989157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Single dose of 60 mg of duloxetine
Study NCT02773290 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Romiplostim
Description: Weekly SC administration
Study NCT00000304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Description: 15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
Study NCT00000304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D-Amphetamine
Description: 30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
Study NCT00000304 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00788073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: STX209
Description: Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
Study NCT00788073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
Study NCT00599950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C and Photorefractive keratectomy (PRK)
Description: Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
Study NCT00599950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Mitomycin C and Photorefractive keratectomy (PRK)
Description: Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
Study NCT04044495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimodal brain imaging (MRI)
Description: Multimodal brain imaging (MRI)
Study NCT04044495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Actimetry
Description: 7 days actimetry
Study NCT04044495 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep Diary
Description: 7 days Record of sleep and wake cycle
Study NCT04016233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir douche
Description: 660 mg TFV in 125 mL hypo-osmolar solution
Study NCT02364622 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Tranditional fiberoptic bronchoscopy
Description: The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
Study NCT02364622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modified fiberoptic bronchoscopy
Description: The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
Study NCT02364622 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible Trachway intubating stylet
Description: The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
Study NCT01161784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics fermented milk
Description: 80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
Study NCT01161784 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient drink
Description: 80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
Study NCT03243942 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Definity
Description: Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
Study NCT02637154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing
Description: Motivational Interviewing method
Study NCT02637154 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Education
Description: Standard Education material will be used
Study NCT01454960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support: Accountable Justification
Description: Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
Study NCT01454960 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audit and Feedback: Peer Comparison
Description: Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
Study NCT05762185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nursing consultation
Description: nursing consultation
Study NCT04353622 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Exoskeleton robot for upper extremity
Description: Robot-assisted Treatment Program:~* 10 minutes elbow flexion/extension~* 10 minutes forearm supination/pronation~* 10 minutes wrist flexion/extension~* 10 minutes ulnar/radial deviation~Frequency: 2/week Duration: 12 sessions (6 weeks)
Study NCT04353622 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physiotherapy
Description: Ferquency: 2/week Duration: 12 sessions (6weeks) Each session: 50 minutes
Study NCT06150105 — intervention group
Intervention type: OTHER
Intervention: Exercise training
Description: Intense endurance training
Study NCT02367885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-850 0.25 mL injection
Description: TAK-850 intramuscular injection